v3.25.1
Segment Information
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Information

9. Segment Information

 

The Company operates and manages its business as one1 reportable and operating segment dedicated to the research and development Company’s novel orally administered antiviral influenza candidate. The measure of segment assets is reported on the balance sheet as total consolidated assets. In addition, the Company manages the business activities on a consolidated basis.

 

The Company’s CODM reviews financial information presented on a consolidated basis and decides how to allocate resources based on net income (loss). 

 

Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM (table in thousands):

 

   2025   2024 
   Three months ended March 31, 
   2025   2024 
Revenue  $-   $- 
           
Less:          
Research and development   1,027    2,509 
Salaries and personnel costs   544    656 
Insurance   62    77 
Stock-based compensation   82    157 
Operating expenses   625    759 
Other income   (39)   (202)
Net loss  $2,301   $3,956